Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages

  Alagkiozidis, Ioannis ^a   Facciabene, Andrea ^a   Carpenito, Carmine ^b   Benencia, Fabian ^b   Jonak, Zdenka ^c   Adams, Sarah ^a   Carroll, Richard G ^b   Gimotty, Phyllis A ^a   Hammond, Rachel ^a   Danet Desnoyers, Gwen äel ^a   June, Carl H ^a,b   Powell Jr, Daniel J ^a   Coukos, George ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FAS ANTIGEN; INTERLEUKIN 18; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; OVARY CANCER; TUMOR CELL; TUMOR REGRESSION; UPREGULATION; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-18; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 73249137169     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-104     Document Type: Article

References (25)

1. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001, 61:3689-3697.
2. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005, 202:1691-1701. 10.1084/jem.20050915, 2212968, 16365148.
3. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13:54-61. 10.1038/nm1523, 17187072.
4. Ehrke MJ, Verstovsek S, Maccubbin DL, Ujhazy P, Zaleskis G, Berleth E, Mihich E. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer 2000, 87:101-109. 10.1002/1097-0215(20000701)87:1<101::AID-IJC15>3.0.CO;2-B, 10861459.
5. Ewens A, Luo L, Berleth E, Alderfer J, Wollman R, Hafeez BB, Kanter P, Mihich E, Ehrke MJ. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res 2006, 66:5419-5426. 10.1158/0008-5472.CAN-05-3963, 16707470.
6. Zhu S, Waguespack M, Barker SA, Li S. Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent antitumor effect. Clin Cancer Res 2007, 13:4252-4260. 10.1158/1078-0432.CCR-06-2894, 17634555.
7. Micallef MJ, Tanimoto T, Kohno K, Ikeda M, Kurimoto M. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 1997, 57:4557-4563.
8. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 1997, 17:3253-3258.
9. Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 2006, 12:4265-4273. 10.1158/1078-0432.CCR-06-0121, 16857801.
10. Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Cancer Res 2000, 60:4838-4844.
11. Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, Bell WN, Thurmond LM, Weisenbach J, Dar MM. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res 2008, 14:3462-3469. 10.1158/1078-0432.CCR-07-4740, 18519778.
12. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213. 10.1056/NEJMoa020177, 12529460.
13. Chu CS, Kim SH, June CH, Coukos G. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 2008, 8:243-257. 10.1586/14737140.8.2.243, 18279065.
14. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000, 21:585-591. 10.1093/carcin/21.4.585, 10753190.
15. Zhang L, Yang N, Garcia JR, Mohamed A, Benencia F, Rubin SC, Allman D, Coukos G. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002, 161:2295-2309. 1850900, 12466143.
16. Benencia F, Courreges MC, Coukos G. Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med 2008, 6:21. 10.1186/1479-5876-6-21, 2408561, 18445282.
17. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 2002, 234-235:119-124. 10.1023/A:1015976430790, 12162424.
18. Gasser S, Raulet DH. The DNA damage response arouses the immune system. Cancer Res 2006, 66:3959-3962. 10.1158/0008-5472.CAN-05-4603, 16618710.
19. Mizutani Y, Okada Y, Yoshida O, Fukumoto M, Bonavida B. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer 1997, 79:1180-1189. 10.1002/(SICI)1097-0142(19970315)79:6<1180::AID-CNCR17>3.0.CO;2-W, 9070496.
20. Tomek S, Horak P, Pribill I, Haller G, Rossler M, Zielinski CC, Pils D, Krainer M. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol 2004, 94:107-114. 10.1016/j.ygyno.2004.04.012, 15262127.
21. Carroll RG, Carpenito C, Shan X, Danet-Desnoyers G, Liu R, Jiang S, Albelda SM, Golovina T, Coukos G, Riley JL. Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. PLoS ONE 2008, 3:e3289. 10.1371/journal.pone.0003289, 2538560, 18818761.
22. Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 1999, 13:2195-2202.
23. Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, Zheng GG, Li G. IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression. Leuk Res 2004, 28:91-95. 10.1016/S0145-2126(03)00121-8, 14630085.
24. Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert B, Moorman PG, Poole C, Anderson AR, Anderson S, Anton-Culver H. Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol Biomarkers Prev 2008, 17:3567-3572. 10.1158/1055-9965.EPI-08-0548, 2664299, 19064572.
25. Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer 2006, 118:1750-1758. 10.1002/ijc.21521, 16217764.